Zydus Lifesciences Limited — Others, 03-03-2025: Action(s) taken or orders passed

Zydus Healthcare Limited has received a penalty of ₹4.27 crore from the Additional Commissioner of CGST & CE for input tax credit issues related to FY 2020-21. The company plans to challenge this order through an appeal. Importantly, there is no material financial impact expected on ZHL or its parent company from this development. This proactive approach to dispute resolution may foster a stable environment for investors, suggesting a neutral impact on sentiment while reflecting the company’s commitment to addressing compliance challenges.